RNA interference (RNAi) is a mechanism in which fragments of double-strand ribonucleic acid (dsRNA) interfere with the expression of a specific gene whose sequence is complementary to the dsRNA. Recently, RNAi medicines, that inhibit the expression of genes responsible for diseases, have been studied actively. However, the delivery of siRNA in vivo had become a big issue because siRNA is unstable in vivo.
KOKEN(Tokyo) developed a new siRNA delivery system, “AteloGene™”. This system is mediated by atelocollagen that is a solubilized collagen obtained by protease treatment, and transfects siRNA in vivo efficiently and safety with each local administration and systemic administration.
Industrial property rights:
Concerning the technique of introducing the nucleic acid component using this kit and collagen, Dainippon Sumitomo Pharma Co., Ltd. and KOKEN Co., Ltd. has either obtained the patent or the patent is under application (PCT/JP02/06137) in Japan and various countries abroad. The usage of this product is limited to application (PCT/JP02/06137) in Japan and various countries abroad. The usage of this product is limited to tests and researches. Other usage of this product may infringe the patent. Please pay attention in this regard.